Cardax Inc. (CDXI)
|Net Income (ttm)||-5.50M|
|Trading Day||January 15|
|Day's Range||1.62 - 1.62|
|52-Week Range||1.15 - 19|
There are no news available yet.
Cardax, a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an anti-inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate; and CDX-301, a zeaxanthin pharmaceutical candidate for pharma... [Read more...]
David G. Watumull
|Stock Exchange |
|Ticker Symbol |
In 2019, Cardax's revenue was $710,949, a decrease of -52.94% compared to the previous year's $1.51 million. Losses were -$5.09 million, 26.6% more than in 2018.
The average 12-month stock price forecast for Cardax is 1.00, which is a decrease of -38.27% from the latest price.